coronaviru
diseas
viral
ill
caus
sever
acut
respiratori
syndrom
coronaviru
deem
pandem
world
health
organ
number
import
cardiovascular
implic
patient
prior
cardiovascular
diseas
higher
risk
advers
event
covid
individu
without
histori
cardiovascular
diseas
risk
incid
cardiovascular
complic
sever
way
pandem
may
affect
prevent
manag
thrombot
thromboembol
diseas
hereaft
collect
refer
thrombot
diseas
breviti
first
direct
effect
indirect
effect
infect
sever
ill
hypoxia
may
predispos
patient
thrombot
event
preliminari
report
suggest
hemostat
abnorm
includ
dissemin
intravascular
coagul
dic
occur
patient
affect
addit
sever
inflammatori
respons
critic
ill
underli
tradit
risk
factor
may
predispos
thrombot
event
similar
prior
virul
zoonot
coronaviru
outbreak
tabl
second
investig
therapi
treat
may
advers
drugdrug
interact
antiplatelet
agent
anticoagul
third
pandem
resourc
alloc
social
distanc
recommend
may
advers
affect
care
patient
without
present
thrombot
event
exampl
mi
percept
antithrombot
agent
confer
increas
risk
contract
may
lead
untoward
interrupt
anticoagul
patient
current
manuscript
author
intern
collabor
clinician
investig
summar
pathogenesi
epidemiolog
treatment
avail
outcom
data
relat
thrombot
diseas
patient
well
manag
thrombot
event
patient
without
pandem
although
focu
prevent
manag
venou
thromboembol
vte
antithrombot
therapi
acut
coronari
syndrom
ac
mani
recommend
relev
condit
requir
antithrombot
therapi
provid
clinic
guidanc
feasibl
also
identifi
area
requir
urgent
attent
futur
research
everi
effort
made
provid
comprehens
assess
publish
evid
medlin
pubm
interfac
date
last
search
april
accommod
rapidlyevolv
natur
inform
concern
delay
complet
studi
public
also
review
manuscript
two
preprint
server
http
wwwmedrxivorg
http
wwwssrncomindexcfmencoronaviru
date
last
search
april
acknowledg
manuscript
latter
two
sourc
peerreview
intern
variabl
prevent
measur
test
strategi
local
author
diagnost
test
avail
access
care
treatment
strategi
well
variabl
outcom
report
issu
influenc
report
diagnos
case
casualti
turn
casefat
rate
moreov
date
lack
larg
prospect
cohort
exist
evid
includ
data
thrombot
complic
deriv
primarili
small
retrospect
analys
figur
current
document
repres
effort
provid
gener
guidanc
patientcar
relat
thrombosi
antithrombot
therapi
given
limit
evid
base
steer
committe
bb
mvm
jiw
sk
szg
mm
hmk
gyhl
chose
sever
question
seem
challeng
relev
patient
care
question
sent
entir
group
author
twice
delphi
method
implement
provid
consensusbas
guidanc
question
includ
consider
prophylact
therapeut
anticoagul
regimen
among
variou
subgroup
patient
antithrombot
therapi
set
suspect
confirm
dic
singlestrand
rna
coronaviru
enter
human
cell
mainli
bind
angiotensin
convert
enzym
highli
express
lung
alveolar
cell
cardiac
myocyt
vascular
endothelium
cell
transmit
primarili
viral
particl
inhal
enter
respiratori
tract
addit
viru
surviv
hour
surfac
depend
type
surfac
enabl
fomit
transmiss
initi
symptom
overlap
viral
syndrom
includ
fever
fatigu
headach
cough
short
breath
diarrhea
headach
myalgia
virul
zoonot
coronaviru
infect
sever
acut
respiratori
syndrom
sar
middl
eastern
respiratori
syndrom
merscov
potenti
result
sever
ill
includ
system
inflammatori
respons
syndrom
acut
respiratori
diseas
syndrom
ard
multiorgan
involv
shock
although
older
age
comorbid
cardiovascular
diseas
confer
higher
risk
sever
diseas
young
otherwis
healthi
patient
also
risk
complic
common
laboratori
abnorm
found
patient
includ
lymphopenia
elev
lactat
dehydrogenas
inflammatori
marker
creactiv
protein
ddimer
ferritin
level
may
correl
diseas
sever
procoagul
profil
consist
hemostat
abnorm
includ
mild
thrombocytopenia
increas
ddimer
level
associ
higher
risk
requir
mechan
ventil
intens
care
unit
icu
admiss
death
data
relat
test
less
certain
often
contradictori
diseas
sever
variabl
associ
prolong
prothrombin
time
pt
intern
normal
ratio
inr
thrombin
time
tt
variabl
trend
toward
shorten
activ
partial
thromboplastin
time
aptt
recent
tang
et
al
assess
patient
die
among
notabl
differ
patient
die
surviv
increas
level
ddimer
fibrin
degrad
product
fdp
increas
respect
pt
prolong
p
patient
die
fulfil
intern
societi
thrombosi
haemostasi
isth
criteria
dic
compar
among
survivor
collect
hemostat
chang
indic
form
coagulopathi
may
predispos
thrombot
event
central
illustr
although
caus
uncertain
nevertheless
yet
unknown
whether
hemostat
chang
specif
effect
consequ
cytokin
storm
precipit
onset
system
inflammatori
respons
syndrom
sir
observ
viral
diseas
anoth
consider
yet
investig
hemostat
chang
seen
infect
relat
liver
dysfunct
recent
studi
report
case
sever
cerebr
infarct
one
associ
bilater
limb
ischemia
set
elev
antiphospholipid
antibodi
whether
antiphospholipid
antibodi
play
major
role
pathophysiolog
thrombosi
associ
requir
investig
elev
troponin
level
associ
poor
outcom
sever
studi
howev
differenti
diagnosi
elev
troponin
broad
includ
nonspecif
myocardi
injuri
impair
renal
function
lead
troponin
accumul
myocard
pulmonari
embol
pe
type
ii
myocardi
infarct
mi
similarli
elev
natriuret
peptid
nonspecif
consider
thrombot
event
eg
pe
rais
appropri
clinic
context
sever
investig
agent
test
manag
especi
patient
develop
sever
diseas
drug
clinic
import
interact
antiplatelet
anticoagul
agent
tabl
investig
agent
associ
excess
risk
case
reduc
risk
thrombot
event
thrombocytopenia
prior
studi
popul
exampl
bevacizumab
monoclon
antibodi
bind
vascular
endotheli
growth
factor
vegf
investig
use
associ
increas
risk
advers
cardiovascular
event
includ
mi
cerebrovascular
accid
vte
altern
fingolimod
immunomodul
agent
tri
may
reduc
reperfus
injuri
improv
outcom
patient
suffer
acut
ischem
stroke
hydroxychorloquin
recent
receiv
emerg
use
author
us
food
drug
administr
treatment
may
potenti
exert
antithrombot
properti
especi
antiphospholipid
antibodi
scientist
studi
number
agent
treatment
may
interact
oral
antiplatelet
agent
tabl
present
potenti
drug
interact
investig
drug
commonli
administ
oral
antiplatelet
agent
lopinavirritonavir
proteas
inhibitor
inhibit
metabol
although
activ
metabolit
clopidogrel
mostli
form
inhibit
may
also
lead
reduct
effect
dosag
clopidogrel
contrast
inhibit
may
increas
effect
ticagrelor
therefor
concomit
use
agent
along
lopinavirritonavir
caution
although
limit
clinic
data
exist
use
platelet
function
test
guid
use
clopidogrel
ticagrelor
set
might
consid
altern
absenc
contraind
use
prasugrel
prone
interact
remdesivir
nucleotideanalog
inhibitor
rnadepend
rna
polymeras
reportedli
induc
howev
dose
adjust
oral
antiplatelet
agent
current
recommend
note
major
drugdrug
interact
investig
therapi
parenter
antiplatelet
agent
cangrelor
glycoprotein
iibiiia
inhibitor
hospit
patient
acut
medic
ill
includ
infect
pneumonia
increas
risk
vte
prophylact
anticoagul
reduc
risk
vte
acut
ill
hospit
medic
patient
appropri
use
vte
prophylaxi
cover
clinic
practic
guidelin
multipl
risk
stratif
tool
avail
vte
risk
assess
set
eg
caprini
improv
padua
model
choic
specif
risk
assess
model
may
vari
across
health
system
howev
similar
acut
ill
medic
patient
vte
risk
stratif
hospit
patient
undertaken
recent
studi
china
use
padua
model
report
hospit
patient
high
risk
vte
studi
provid
data
use
vte
prophylaxi
incid
vte
event
hospit
patient
respiratori
failur
comorbid
eg
activ
cancer
heart
failur
patient
bedridden
requir
intens
care
receiv
pharmacolog
vte
prophylaxi
unless
contraind
choic
agent
dose
base
avail
guidelin
recommend
world
health
organ
interim
guidanc
statement
recommend
prophylact
daili
lowmolecular
weight
heparin
lmwh
twice
daili
subcutan
unfraction
heparin
ufh
pharmacolog
prophylaxi
contraind
mechan
vte
prophylaxi
intermitt
pneumat
compress
consid
immobil
patient
miss
dose
pharmacolog
vte
prophylaxi
common
like
associ
wors
outcom
therefor
everi
effort
made
ensur
patient
receiv
schedul
dose
pharmacolog
vte
prophylaxi
regard
daili
dose
regimen
lmwh
may
advantag
ufh
reduc
person
protect
equip
ppe
use
exposur
healthcar
worker
consider
risk
vte
pregnant
patient
deserv
attent
risk
vte
increas
pregnanc
postpartum
period
although
limit
data
avail
pregnant
women
admit
hospit
infect
like
increas
risk
vte
reason
assess
risk
vte
consid
pharmacolog
thromboprophylaxi
especi
vte
risk
factor
weightadjust
prophylact
dose
anticoagul
interest
topic
requir
addit
investig
hospit
discharg
acut
medic
ill
extend
prophylaxi
lmwh
direct
oral
anticoagul
doac
reduc
risk
vte
cost
increas
bleed
event
includ
major
bleed
data
specif
exist
reason
employ
individu
risk
stratif
thrombot
hemorrhag
risk
follow
consider
extend
prophylaxi
day
patient
elev
risk
vte
eg
reduc
mobil
comorbid
activ
cancer
accord
author
write
group
elev
ddimer
time
upper
normal
limit
low
risk
bleed
role
thromboprophylaxi
quarantin
patient
mild
signific
comorbid
patient
without
less
activ
quarantin
uncertain
patient
advis
stay
activ
home
absenc
highqual
data
pharmacolog
prophylaxi
reserv
highest
risk
patient
includ
limit
mobil
histori
prior
vte
activ
malign
describ
elev
ddimer
level
common
find
patient
current
warrant
routin
investig
acut
vte
absenc
clinic
manifest
support
inform
howev
index
suspicion
vte
high
case
typic
dvt
symptom
hypoxemia
disproportion
known
respiratori
patholog
acut
unexplain
right
ventricular
dysfunct
diagnost
challeng
aris
among
patient
imag
studi
use
diagnos
dvt
pe
may
pursu
given
risk
transmit
infect
patient
healthcar
worker
potenti
due
patient
instabl
moreov
imag
studi
may
challeng
set
patient
sever
ard
requir
prone
posit
investig
pe
feasibl
due
critic
ill
prone
posit
lower
extrem
ultrasound
also
limit
due
patient
posit
deterior
right
ventricular
function
set
may
critic
find
justifi
need
way
diagnos
treat
pe
howev
may
argu
prognosi
patient
ard
requir
prone
posit
grave
investig
underli
vte
may
alter
cours
potenti
option
may
consid
echocardiographi
assess
sign
potenti
worsen
right
ventricular
dysfunct
rare
circumst
clot
transit
view
hemostat
derang
discuss
observ
prior
viral
ill
clinician
use
intermediatedos
full
dose
therapeut
parenter
anticoagul
rather
prophylact
dose
routin
care
patient
hypothes
may
confer
benefit
prevent
microvascular
thrombosi
howev
exist
data
limit
primarili
base
subgroup
analysi
singl
retrospect
studi
limit
control
potenti
confound
singl
center
studi
china
suggest
ddimer
level
sensit
specif
detect
vte
event
howev
studi
limit
small
sampl
publish
studi
comment
incid
vte
patient
retrospect
studi
china
among
patient
sever
admit
icu
develop
incid
vte
note
none
patient
receiv
vte
prophylaxi
preprint
studi
patient
wuhan
suspect
pe
underw
comput
tomographi
angiographi
cta
evid
acut
pe
imag
http
howev
studi
provid
inform
relat
use
vte
prophylaxi
reason
perform
cta
studi
patient
sever
academ
medic
center
netherland
author
report
ci
patient
develop
incid
vte
patient
receiv
pharmacolog
prophylaxi
although
underdos
observ
particip
center
find
requir
valid
addit
studi
possibl
unknown
vte
remain
underdiagnos
patient
sever
import
ard
patient
potenti
etiolog
hypox
pulmonari
vasoconstrict
pulmonari
hypertens
right
ventricular
failur
insult
pe
may
unrecover
therapeut
anticoagul
mainstay
vte
treatment
select
agent
requir
consider
comorbid
renal
hepat
dysfunct
thrombocytopenia
gastrointestin
tract
function
agent
like
chang
across
hospit
cours
time
discharg
mani
ill
inpati
vte
parenter
anticoagul
eg
ufh
prefer
may
temporarili
withheld
known
drugdrug
interact
investig
therapi
concern
ufh
howev
includ
time
achiev
therapeut
aptt
increas
healthcar
worker
exposur
frequent
blood
draw
therefor
lmwh
may
prefer
patient
unlik
need
procedur
benefit
oral
anticoagul
doac
includ
lack
need
monitor
facilit
discharg
plan
outpati
manag
potenti
risk
especi
set
organ
dysfunct
may
includ
clinic
deterior
lack
time
avail
effect
revers
agent
center
patient
readi
discharg
doac
lmwh
would
prefer
limit
contact
patient
healthcar
servic
requir
inr
monitor
vka
pulmonari
embol
respons
team
pert
allow
multidisciplinari
care
patient
intermedi
highrisk
vte
pandem
similar
consult
servic
pert
transit
inperson
inpati
evalu
econsult
use
phone
call
telemedicin
system
whenev
feasibl
import
note
minim
avail
data
demonstr
lower
mortal
routin
use
advanc
vte
therapi
therefor
use
catheterdirect
therapi
current
outbreak
limit
critic
situat
indiscrimin
use
inferior
vena
cava
filter
avoid
recurr
pe
despit
optim
anticoagul
clinicallysignific
vte
set
absolut
contraind
anticoagul
would
among
scenario
placement
inferior
vena
cava
filter
may
consid
even
ivc
filter
placement
anticoagul
resum
soon
feasibl
often
done
gradual
increas
dose
close
observ
bleed
regard
reperfus
strategi
acut
pe
current
guidelin
recommend
follow
known
posit
uncertain
statu
rather
support
strategi
requir
use
catheter
laboratori
oper
room
figur
present
potenti
algorithm
treatment
base
risk
due
vte
sever
vast
major
patient
symptomat
acut
deep
venou
thrombosi
dvt
manag
anticoagul
home
treatment
whenev
possibl
may
requir
acut
endovascular
techniqu
either
local
fibrinolysi
embolectomi
includ
phlegmasia
truli
refractori
symptom
myocardi
injuri
evidenc
elev
cardiac
troponin
level
electrocardiograph
echocardiograph
abnorm
associ
sever
diseas
furthermor
higher
troponin
level
associ
sever
howev
event
due
thrombot
ac
anecdot
case
patient
present
ac
due
plaqueruptur
describ
type
mi
current
case
publish
case
also
previous
describ
influenza
viral
ill
attribut
combin
sir
well
local
vascularplaqu
inflamm
present
consist
ac
due
plaqu
ruptur
ie
type
mi
dual
antiplatelet
therapi
dapt
full
dose
anticoagul
per
american
colleg
cardiolog
acc
american
heart
associ
aha
european
societi
cardiolog
esc
guidelin
administ
unless
contraind
patient
perceiv
elev
bleed
risk
regimen
less
potent
antiplatelet
agent
clopidogrel
consid
given
hemorrhag
complic
uncommon
special
attent
also
given
drugdrug
interact
antiplatelet
agent
anticoagul
investig
therapi
parenter
antithrombot
agent
gener
known
major
interact
investig
therapi
tabl
angiographi
intervent
scai
recent
provid
guidanc
regard
catheter
laboratori
procedur
current
climat
recommend
note
reason
continu
optim
medic
therapi
defer
nonurg
cardiac
procedur
order
preserv
ppe
hospit
resourc
includ
inpati
icu
bed
minim
exposur
patient
healthcar
worker
alik
prior
intervent
effort
made
distinguish
nonspecif
myocardi
injuri
myocard
true
plaqu
ruptur
present
low
threshold
use
transthorac
echocardiographi
identifi
wall
motion
abnorm
consid
prior
catheter
laboratori
activ
even
case
stemi
primari
percutan
coronari
intervent
pci
reduc
mortal
reinfarct
risk
transmiss
patient
healthcar
worker
vice
versa
asymptomat
vector
must
consid
light
individu
center
china
elsewher
develop
adjust
ac
protocol
call
consider
fibrinolyt
therapi
select
patient
stemi
center
time
percutan
coronari
intervent
less
feasibl
may
like
adopt
strategi
howev
given
present
mimic
ac
eg
set
myocard
fibrinolyt
therapi
must
use
caution
risk
vte
increas
critic
ill
patient
like
even
higher
critic
ill
asid
hemostat
derang
immobl
system
inflammatori
state
mechan
ventil
central
venou
cathet
contribut
vte
risk
within
icu
nutrit
defici
liver
dysfunct
may
also
interfer
product
coagul
factor
alter
pharmacokinet
critic
ill
patient
may
necessit
anticoagul
dose
adjust
due
factor
relat
absorpt
metabol
renal
hepat
elimin
drug
set
potenti
organ
dysfunct
parenter
anticoagul
recommend
case
anticoagul
therapi
need
known
thrombot
diseas
ufh
use
set
anticip
procedur
patient
deterior
renal
function
urgent
procedur
anticip
lmwh
reason
altern
patient
requir
ecmo
anticoagul
frequent
requir
maintain
circuit
patenc
especi
lower
flow
set
rate
complic
unknown
patient
rate
thrombosi
hemorrhag
may
high
respect
popul
respiratori
failur
limit
outcom
data
avail
ecmo
patient
suggest
poor
outcom
patient
die
one
seri
anoth
current
insuffici
data
recommend
anticoagul
target
patient
requir
ecmo
previous
mention
sever
may
predispos
dic
patient
experienc
particularli
poor
outcom
support
care
address
underli
hypoxia
coinfect
appropri
insuffici
data
recommend
transfus
threshold
differ
recommend
critic
ill
patient
invas
procedur
plan
prophylact
transfus
platelet
fresh
frozen
plasma
fibrinogen
prothrombin
complex
concentr
may
consid
lastli
patient
requir
target
temperatur
manag
may
exhibit
prolong
pt
aptt
without
evid
bleed
diathesi
therefor
correct
coagulopathi
unselect
patient
without
overt
bleed
current
recommend
dic
common
mani
patient
critic
ill
includ
uncertain
whether
uniqu
characterist
caus
direct
activ
coagul
diagnosi
dic
best
establish
use
isth
dic
score
calcul
regular
laboratori
monitor
platelet
count
pt
ddimer
fibrinogen
patient
import
diagnos
worsen
coagulopathi
first
step
manag
dic
identifi
treat
underli
condit
bacteri
superinfect
treat
aggress
addit
prevent
vte
lmwh
prophylaxi
may
decreas
thrombin
gener
modifi
cours
dic
preliminari
result
albeit
small
number
event
limit
adjust
may
suggest
favor
respons
lmwh
prophylaxi
longact
antiplatelet
agent
gener
discontinu
patient
dic
unless
requir
eg
recent
ac
stent
implant
patient
moder
sever
indic
dual
antiplatelet
therapi
eg
pci
within
past
month
recent
mi
suspect
confirm
dic
without
overt
bleed
absenc
evid
decis
antiplatelet
therapi
need
individu
gener
reason
continu
dual
antiplatelet
therapi
platelet
count
reduc
singl
antiplatelet
therapi
count
discontinu
platelet
howev
guidelin
may
revis
upward
downward
depend
individu
rel
risk
stentrel
thrombot
complic
vs
bleed
recoveri
dic
depend
endogen
fibrinolysi
break
dissemin
thrombi
clinicallyovert
bleed
uncommon
set
howev
bleed
occur
dic
blood
product
support
consid
per
septic
coagulopathi
summari
mainstay
blood
product
transfus
follow
platelet
concentr
maintain
platelet
count
l
dic
patient
activ
bleed
l
high
risk
bleed
requir
invas
procedur
main
goal
manag
patient
known
newonset
thrombot
diseas
without
provid
suffici
antithrombot
protect
minim
physic
contact
patient
healthcar
worker
health
system
outpati
manag
earli
discharg
acut
vte
institut
possibl
earli
discharg
medic
stabil
lowrisk
ac
pci
highrisk
ac
consid
telemedicin
prefer
method
followup
inperson
visit
reserv
scenario
address
telemedicin
may
potenti
warrant
hospit
gener
pharmacotherapi
patient
known
thrombot
diseas
without
follow
similar
period
prior
pandem
although
recent
document
cdc
indic
increas
risk
sever
patient
receiv
blood
thinner
evid
antiplatelet
agent
anticoagul
increas
risk
contract
develop
sever
suffici
educ
provid
patient
selfmonitor
symptom
avoid
unnecessari
emerg
depart
visit
nuisanc
bleed
patient
receiv
vka
frequent
inr
monitor
may
pose
logist
challeng
due
lockdown
may
unnecessarili
increas
risk
expos
therefor
thought
consider
given
potenti
altern
includ
use
extend
inr
test
interv
prior
inr
stabl
altern
includ
homebas
inr
check
set
promptli
drivethrough
inr
test
switch
doac
lmwh
clinic
appropri
figur
summari
key
recommend
present
tabl
consider
healthcar
worker
cdc
recommend
contact
droplet
person
ppe
healthcar
worker
routin
care
patient
aerosolgener
procedur
perform
eg
intub
extub
cardiopulmonari
resuscit
addit
airborn
ppe
respir
recommend
use
telemedicin
place
inperson
offic
visit
strategi
minim
physic
exposur
detail
discuss
elsewher
follow
consider
specif
care
patient
thrombot
diseas
may
use
overth
phone
telemedicin
approach
consid
nonurg
appoint
necessari
inperson
visit
visitor
restrict
stagger
appoint
import
consider
patient
requir
urgent
procedur
intervent
ac
highrisk
pe
critic
limb
ischemia
fewest
number
staff
necessari
involv
patient
without
known
infect
healthcar
worker
screen
patient
exposur
infect
consid
appropri
ppe
procedur
appli
disinfect
techniqu
postprocedur
outlin
previous
patient
requir
emerg
cardiac
catheter
unknown
statu
airborn
ppe
respir
andor
power
air
purifi
respir
recommend
activ
involv
health
system
respect
care
patient
thrombot
diseas
critic
achiev
good
outcom
uninfect
patient
feasibl
resourc
alloc
enabl
athom
drivethrough
inr
check
systembas
consider
made
monitor
make
necessari
adjust
algorithm
manag
suspect
stemi
sever
pe
requir
pert
team
procedur
deem
necessari
infect
patient
specif
protocol
put
place
regard
ppe
use
room
disinfect
figur
govern
agenc
recogn
critic
import
public
health
intervent
societ
level
includ
social
distanc
selfisol
decreas
transmiss
rate
allevi
burden
health
system
affect
area
govern
enact
mandatori
home
quarantin
nonessenti
personnel
sever
import
issu
consid
intervent
relat
thrombot
diseas
first
given
recommend
stay
home
decreas
daili
activ
sedentari
lifestyl
patient
may
increas
risk
vte
clinician
awar
especi
older
adult
higherrisk
patient
provid
educ
import
home
activ
mitig
risk
second
daili
routin
disrupt
dietari
chang
especi
daili
intak
green
veget
major
sourc
vitamin
k
western
diet
may
affect
patient
receiv
vka
quarantin
measur
becom
sever
chang
diet
vitamin
k
intak
may
impact
inr
valu
provid
patient
awar
risk
patient
advis
maintain
stabl
diet
best
abil
third
pandem
produc
damag
econom
effect
unit
nation
estim
like
cost
world
economi
trillion
loss
may
advers
affect
patient
treatment
thrombot
diseas
socioeconom
disadvantag
link
higher
rate
vte
advers
outcom
econom
effect
continu
evolv
commun
may
come
new
signific
stress
data
higherqu
data
requir
learn
thrombot
diseas
interact
data
ideal
deriv
prospect
multicent
multin
studi
could
help
elucid
similar
distinct
diseas
present
outcom
patient
preexist
incid
thromboembol
diseas
help
identifi
manag
strategi
optim
outcom
patient
current
one
larg
intern
registri
patient
venou
thromboembol
registro
informatizado
dedic
adjud
prospect
registri
studi
cardiovascular
outcom
initi
coronavt
bwh
thrombosi
research
group
pi
g
piazza
multicent
multin
ac
registri
begun
new
aha
registri
cardiovascular
care
outcom
patient
special
attent
also
given
patient
preexist
thromboembol
diseas
limit
access
care
face
pandem
hinder
transport
limit
resourc
healthcar
system
fund
agenc
profession
societi
organ
activ
patient
particip
play
import
role
come
futur
research
area
fund
agenc
includ
nation
institut
health
alreadi
respond
swiftli
continu
pay
specif
attent
pandem
coordin
cooper
necessari
quickli
address
research
prioriti
includ
relat
thrombot
diseas
tabl
pandem
guidanc
supplement
rather
supplant
clinic
decisionmak
nuanc
convers
patient
practition
consid
appropri
patientcent
decis
conclus
thrombot
diseas
may
preced
factor
incid
complic
patient
import
consider
prevent
therapeut
use
antithrombot
agent
kept
mind
mitig
thrombot
hemorrhag
event
highrisk
patient
fund
agenc
profession
societi
patient
clinician
investig
work
collabor
effect
effici
address
numer
critic
area
knowledg
gap
thrombosi
initi
seri
suggest
common
occurr
venou
thromboembol
diseas
patient
sever
optim
prevent
strategi
warrant
investig
investig
therapi
consid
administ
dose
administ
initi
dose
mg
twice
daili
decreas
dose
mg
follow
mg
daili
coadminist
pgp
inhibit
coadminist
drug
studi
treat
includ
bevacizumab
chloroquinehydroxychloroquin
eculizumab
fingolimod
losartan
pirfenidon
drugdrug
interact
medic
oral
anticoagul
yet
identifi
bevacizumab
report
caus
deep
vein
thrombosi
arteri
thrombosi
pulmonari
embol
also
report
caus
thrombocytopenia
parenter
anticoagul
includ
unfraction
lowmolecular
weight
heparin
bivalirudin
argatroban
fondaparinux
non
cyp
metabol
nt
interact
investig
agent
report
interferon
alpha
recommend
base
us
packag
insert
canadian
packag
insert
consid
combin
agent
contraind
report
caus
pulmonari
embol
thrombosi
decreas
platelet
count
formul
ischem
stroke
report
caus
decreas
platelet
count
decreas
less
mm
patient
mg
mg
dose
respect
cyp
cytochrom
p
system
determin
optim
method
risk
assess
outpati
mild
risk
vte
option
includ
caprini
model
improv
model
padua
model
other
assess
risk
vte
weigh
risk
bleed
determin
incid
acut
coronari
syndrom
populationbas
studi
patient
moder
sever
without
dic
hospit
determin
incid
predictor
vte
among
patient
present
respiratori
insuffici
andor
hemodynam
instabl
includ
lower
extrem
dvt
centrallin
associ
dvt
upper
lower
extrem
also
pe
prospect
multicent
cohort
observ
data
need
protocol
interfer
could
run
parallel
intervent
trial
plan
alreadi
underway
develop
appropri
algorithm
diagnosi
incid
vte
patient
ddimer
elev
mani
inpati
although
neg
valu
may
still
help
case
worsen
hypoxemia
ctpa
may
consid
instead
noncontrast
ct
assess
pulmonari
parenchyma
unresolv
issu
includ
diagnost
test
criticallyil
patient
includ
prone
posit
limit
option
ctpa
ultrasonographi
determin
optim
total
durat
prophylact
anticoagul
ultrasound
screen
select
patient
may
need
studi
determin
optim
dose
prophylact
anticoagul
specif
popul
eg
obes
advanc
kidney
diseas
weightadjust
prophylact
dose
patient
obes
dose
base
creatinin
clearanc
patient
kidney
diseas
requir
investig
determin
lmwh
constitut
prefer
method
pharmacolog
prophylaxi
determin
optim
method
risk
stratif
vte
prophylaxi
hospit
discharg
option
includ
caprini
model
improv
model
padua
model
other
assess
risk
vte
weigh
risk
bleed
determin
routin
use
higher
dose
anticoagul
ie
higher
prophylact
dose
describ
intern
guidelin
confer
net
benefit
import
question
would
whether
monitor
antixa
activ
would
prefer
aptt
determin
incid
predictor
type
acut
myocardi
infarct
patient
compar
process
measur
outcom
noninfect
patient
determin
potenti
role
agent
includ
danaparoid
fondaparinux
sulodexid
select
patient
moderatesever
determin
routin
use
pharmacolog
vte
prophylaxi
low
standard
dose
anticoagul
ufh
lmwh
warrant
overt
bleed
relev
question
whether
prophylact
dose
anticoagul
given
patient
dic
bleed
even
without
immobl
determin
addit
clinic
characterist
variabl
set
dic
eg
lymphopenia
consid
help
riskstratifi
assess
prognosi
determin
util
intervent
includ
antithrombin
concentr
patient
without
comorbid
homebound
pandem
determin
optim
method
screen
risk
stratif
consider
vte
prophylaxi
option
includ
caprini
model
improv
model
padua
model
other
assess
risk
vte
weigh
risk
bleed
conduct
populationlevel
studi
determin
trend
incid
outcom
thrombot
diseas
period
reduc
offic
visit
although
telemedicin
reason
control
pandem
potenti
advers
consequ
noncommunic
diseas
includ
thrombot
diseas
deserv
investig
aptt
activ
partial
thromboplastin
time
coronaviru
diseas
ctpa
comput
tomographi
pulmonari
angiographi
lmwh
lowmolecular
weight
heparin
pe
pulmonari
embol
vte
venou
thromboembol
patient
mild
outpati
outpati
mild
increas
mobil
encourag
although
indiscrimin
use
pharmacolog
vte
prophylaxi
pursu
assess
risk
vte
bleed
reason
pharmacolog
prophylaxi
could
consid
risk
assess
individu
case
basi
patient
elev
risk
vte
without
high
bleed
risk
known
risk
develop
sever
due
take
antithrombot
agent
ie
antiplatelet
agent
anticoagul
patient
take
antithrombot
agent
prior
known
thrombot
diseas
continu
antithrombot
agent
recommend
outpati
vitamin
k
antagonist
recent
stabl
inr
unabl
undergo
home
drivethrough
inr
test
reason
transit
treatment
doac
contraind
problem
drug
avail
afford
doac
approv
avail
lowmolecular
weight
heparin
consid
altern
patient
moder
sever
without
dic
hospit
hospit
patient
undergo
risk
stratif
vte
prophylaxi
hospit
patient
dic
prophylact
dose
anticoagul
administ
prevent
vte
pharmacolog
prophylaxi
contraind
reason
consid
intermitt
pneumat
compress
hospit
patient
dic
insuffici
data
consid
routin
therapeut
intermediatedos
parenter
anticoagul
ufh
lmwh
routin
screen
vte
eg
bilater
lower
extrem
ultrasound
hospit
patient
elev
ddimer
ngml
recommend
point
patient
moder
sever
suspect
confirm
dic
hospit
patient
moder
sever
dic
without
overt
bleed
prophylact
anticoagul
administ
hospit
patient
suspect
confirm
dic
overt
bleed
insuffici
data
consid
routin
therapeut
intermediatedos
parenter
anticoagul
ufh
lmwh
patient
moder
sever
chronic
therapeut
anticoagul
develop
suspect
confirm
dic
without
overt
bleed
reason
consid
indic
anticoagul
weigh
risk
bleed
make
clinic
decis
regard
dose
adjust
discontinu
major
author
manuscript
recommend
reduc
intens
anticoagul
clinic
circumst
unless
risk
thrombosi
consid
exceedingli
high
patient
moder
sever
indic
dual
antiplatelet
therapi
eg
percutan
coronari
intervent
within
past
month
recent
myocardi
infarct
suspect
confirm
dic
without
overt
bleed
absenc
evid
decis
antiplatelet
therapi
need
individu
gener
reason
continu
dual
antiplatelet
therapi
platelet
count
reduc
singl
antiplatelet
therapi
platelet
count
discontinu
platelet
howev
guidelin
may
revis
upward
downward
depend
individu
rel
risk
thrombot
complic
vs
bleed
patient
admit
discharg
routin
screen
vte
risk
reason
consider
pharmacolog
prophylaxi
day
postdischarg
pharmacolog
prophylaxi
consid
elev
risk
thrombot
event
without
high
bleed
risk
ambul
physic
activ
encourag
patient
present
ac
present
concern
stemi
clinician
weigh
risk
sever
stemi
present
potenti
sever
patient
well
risk
individu
clinician
healthcar
system
larg
decis
primari
percutan
coronari
intervent
fibrinolyt
therapi
inform
assess
patient
without
previouslyknown
thrombot
diseas
known
risk
develop
sever
due
take
antithrombot
agent
patient
continu
antithrombot
agent
recommend
minim
risk
associ
healthcar
worker
patient
inperson
interact
followup
evisit
telemedicin
prefer
case
patient
without
develop
new
thrombot
diseas
minim
risk
associ
healthcar
worker
patient
inperson
interact
inhom
treatment
earli
discharg
priorit
minim
risk
associ
healthcar
worker
patient
inperson
interact
followup
evisit
telemedicin
prefer
case
patient
without
comorbid
condit
eg
prior
vte
activ
cancer
major
cardiopulmonari
diseas
homebound
pandem
recommend
includ
increas
mobil
risk
assess
risk
vte
risk
bleed
reason
administr
pharmacolog
prophylaxi
could
consid
risk
assess
individu
case
basi
patient
elev
risk
thrombot
event
without
high
bleed
risk
indic
recommend
reach
consensu
least
author
determin
via
delphi
method
highqual
data
lack
panel
member
consid
reason
use
intermitt
pneumat
compress
patient
sever
addit
pharmacolog
prophylaxi
specif
area
concern
includ
limit
data
use
prone
posit
well
potenti
high
incid
preexist
asymptomat
dvt
vte
prophylaxi
consid
enoxaparin
daili
similar
lmwh
regimen
eg
dalteparin
daili
administ
subcutan
heparin
twice
three
time
per
day
consid
patient
renal
dysfunct
ie
creatinin
clearanc
mlmin
major
write
group
make
recommend
group
favor
intermediatedos
anticoagul
eg
enoxaparin
enoxaparin
bid
ufh
target
aptt
consid
therapeut
anticoagul
major
investig
recommend
routin
vte
screen
howev
remain
member
group
recommend
consid
test
major
investig
recommend
prophylact
anticoagul
minor
investig
vote
intermediatedos
parenter
anticoagul
set
consid
therapeut
anticoagul
major
investig
vote
reduc
intens
anticoagul
indic
acut
survey
question
meet
prespecifi
cutoff
major
write
group
recommend
prophylaxi
doac
minor
recommend
lmwh
avail
appropri
ac
acut
coronari
syndrom
doac
direct
oral
anticoagul
lmwh
lowmolecular
weight
heparin
stemi
stsegment
elev
myocardi
infarct
ufh
unfraction
heparin
vte
venou
thromboembol
